Correct Answer: B. Lamivudine + Tenofovir + Dolutegravir for 4 weeks
Post-exposure prophylaxis (PEP) for occupational HIV exposure requires a triple antiretroviral regimen started within 2 hours (ideally) and no later than 72 hours of exposure. The Indian National AIDS Control Organization (NACO) guidelines recommend a 2 NRTI backbone + 1 integrase inhibitor as the preferred regimen for occupational PEP. Lamivudine and Tenofovir form the dual NRTI backbone—both have excellent bioavailability, good tissue penetration, and minimal drug interactions. Dolutegravir (an integrase strand transfer inhibitor) is the preferred third agent because it has: (1) rapid viral suppression, (2) high barrier to resistance, (3) minimal hepatotoxicity, (4) no need for boosting, and (5) excellent safety profile in acute exposure settings. The 4-week duration aligns with NACO and WHO guidelines for occupational PEP. Dolutegravir has largely replaced efavirenz and nevirapine in modern regimens due to superior tolerability and lower neuropsychiatric side effects—critical for healthcare workers who must remain functional during the anxiety-laden post-exposure period.
Why the other options are wrong
A. Lamivudine + Tenofovir + Efavirenz for 4 weeks — While this was an acceptable PEP regimen historically, efavirenz is no longer preferred for occupational PEP in current NACO guidelines. Efavirenz carries significant neuropsychiatric side effects (dizziness, insomnia, depression, impaired concentration)—unacceptable in a healthcare worker managing anxiety post-exposure. Dolutegravir has replaced it as the preferred integrase inhibitor due to better tolerability and faster viral suppression. C. Zidovudine + Lamivudine for 4 weeks — This is a dual NRTI regimen only—it lacks the critical third agent (integrase inhibitor or NNRTI). Dual therapy is inadequate for PEP and carries unacceptably high risk of treatment failure and resistance development. Current guidelines mandate triple therapy. Additionally, zidovudine causes bone marrow suppression and gastrointestinal toxicity, making it suboptimal for occupational PEP when better-tolerated alternatives exist. D. Zidovudine + Lamivudine + Nevirapine for 4 weeks — Although triple therapy, this regimen is outdated for occupational PEP. Nevirapine carries significant hepatotoxicity risk and requires careful monitoring—inappropriate for acute exposure settings. Zidovudine causes bone marrow suppression and GI intolerance. Modern guidelines favor the 2 NRTI + integrase inhibitor backbone (specifically dolutegravir) over NNRTI-based regimens for occupational PEP due to superior safety and efficacy profiles.
High-Yield Facts
- Occupational HIV PEP regimen: 2 NRTIs (lamivudine + tenofovir) + 1 integrase inhibitor (dolutegravir preferred) for 4 weeks per NACO guidelines.
- Dolutegravir advantages: High barrier to resistance, rapid viral suppression, no hepatotoxicity, no need for ritonavir boosting, minimal neuropsychiatric side effects.
- PEP timing window: Ideally within 2 hours; maximum efficacy up to 72 hours post-exposure; efficacy drops significantly beyond 72 hours.
- Efavirenz and nevirapine: Replaced by dolutegravir in modern PEP regimens due to neuropsychiatric toxicity and hepatotoxicity respectively.
- Baseline testing required: HIV serology, CD4 count, viral load, and resistance testing of source patient before initiating PEP.
Mnemonics
PEP Triple Therapy Rule 2 + 1 = PEP: 2 NRTIs (TDF + 3TC) + 1 Integrase inhibitor (DTG). Remember: Tenofovir + Lamivudine + Dolutegravir is the modern gold standard. Why DTG over EFV/NVP DTG = Durable, Tolerable, Good: Dolutegravir has no neuro-toxicity (unlike EFV) and no hepato-toxicity (unlike NVP)—ideal for stressed healthcare workers.
NBE Trap
NBE may lure candidates toward option A (efavirenz) by presenting it as a "classic triple therapy"—but modern NACO guidelines have shifted to dolutegravir for occupational PEP. The trap exploits outdated knowledge; students who memorized older regimens will select the wrong answer.
Clinical Pearl
In Indian tertiary care settings, occupational needlestick injuries are common among resident doctors and nursing staff. Rapid initiation of dolutegravir-based PEP within the 72-hour window—combined with counseling and adherence support—reduces seroconversion risk from ~0.3% to <0.05%. Always document the source patient's viral load and resistance profile to guide PEP intensity.
_Reference: NACO Guidelines on Post-Exposure Prophylaxis (2019); Park's Textbook of Preventive and Social Medicine, Ch. 8 (National Health Programs)_